The Strategic Innovation Fund (SIF) is the program of Innovation, Science and Economic Development Canada designed to support the "Canadian innovation ecosystem,"[1] which includes providing "funding to innovative sectors" such as "advanced manufacturing, agri-food, clean technology, clean resources, digital industries, and health and biosciences."[2][3][4] The SIF covers all sectors of the Canadian economy and is available to both for-profit and not-for profit organizations.[1]
It supports those large-scale projects that help position Canada's interests in the global knowledge-based economy, promoting the long-term competitiveness of Canadian industries, clean growth, and the "advancement of Canada's strategic technological advantage."[1] With a single, streamlined fund, it provides businesses with access to a simpler application process, more timely processing, and responsive assistance.[5]
Since the 2018 Canadian federal budget, the SIF now only provides funds in chunks of over $10 million.[8] In June that year, the SIF was the mechanism of support for the steel and aluminum industries of Canada when the Trump Administration placed customs duties on them.[8]
On 20 March 2020, the Canadian government announced a plan to ramp up production of medical equipment, switching assembly lines to produce ventilators, masks, and other personal protective gear. Companies would be able to access funds through the SIF. Trudeau stated that Canadian medical supply firms Thornhill Medical, Medicom, and Spartan Bioscience were looking to expand production. To address shortages and supply-chain disruption, Canada passed emergency legislation that waived patent protection, giving government-selected companies or organizations the right to produce patented products without permission from the patent holder.[12] According to the Bains, "the country's entire industrial policy will be refocused to prioritize the fight against COVID-19."[13][14]
Projects
Recent projects of SIF, as of September 2021[update], include:[4]
In the wake of the COVID-19 pandemic, the SIF was designated by the Canadian government in March 2020 to deliver the Medical Countermeasures (MCM) initiative and was given authority to invest $792 million to fund clinical trials and manufacturing capacity at scale. The MCM funding stream is divided into three types of projects: vaccines, therapies, and biomanufacturing projects.